★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Thermo Fisher Scientific Inc. (TMO) Moat Analysis
Thermo Fisher Scientific Inc.
TMO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Thermo Fisher reports Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Q1 2026 external-revenue mix was 20.2%, 15.1%, 10.2% and 54.5%, while Life Sciences contributed 39.8% of rounded segment income. The clearest advantages are instrument and workflow-linked consumables, proprietary assay formats, trusted research brands, global technical service, and an embedded laboratory procurement channel. Ordinary diagnostics regulation is not independently scored, and broad outsourced-services scope does not by itself prove scarce capacity. The distribution score is moderated because Avantor and other scaled rivals offer similar catalogs. Customer budget cycles, dual-sourcing, open consumables, instrument capex cycles and CDMO/CRO competition remain key risks.
Primary segment
Laboratory Products and Biopharma Services
Market structure
Competitive
Market share
—
HHI: —
Coverage
4 segments · 7 tags
Updated 2026-07-12
Segments
Life Sciences Solutions
Life science research tools and bioprocessing consumables/instruments
Revenue
20.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Analytical Instruments
Analytical instruments (chromatography, mass spectrometry, electron microscopy) with consumables and services
Revenue
15.1%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Specialty Diagnostics
Specialty diagnostics (immunodiagnostics, microbiology, transplant diagnostics) and related consumables
Revenue
10.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Laboratory Products and Biopharma Services
Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)
Revenue
54.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Life Sciences Solutions
Life science research tools and bioprocessing consumables/instruments
Revenue_share uses Q1 2026 external-customer revenue of $2.219B divided by consolidated revenue of $11.005B. Operating_profit_share uses segment income of $954M normalized across $2.400B of rounded segment income. Source: Q1 2026 Form 10-Q.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Reagents/consumables attached to instruments and single-use bioproduction workflows create recurring pull-through once adopted and validated in lab processes.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Protocol standardization on open reagents reduces consumables differentiation
- Pricing pressure as competitors bundle similar bioprocessing consumables
- Funding cycles (NIH/academia) and biopharma demand volatility
Leading indicators
- Consumables mix vs instruments mix
- Attach rate of proprietary reagents/kits to installed base
- Gross margin trend in Life Sciences Solutions
Counterarguments
- Many workflows can be multi-sourced (reagents and plastics) with limited switching cost
- Large customers can negotiate aggressively using dual sourcing
Format Lock In
Demand
Format Lock In
Strength
Durability
Confidence
Evidence
Genetic science platforms often pair instruments with related reagents, which can create assay format/workflow dependence over time.
Format Lock In moat: definition, examples, and stocks
Erosion risks
- Open-source methods and third-party reagents reduce platform dependence
- New modalities can bypass incumbent instrument/reagent formats
Leading indicators
- Share of segment revenue from proprietary reagents/kits
- Installed base growth/decline for key platforms
Counterarguments
- Labs often run mixed fleets and use cross-compatible consumables where possible
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Well-known brands (e.g., Thermo Scientific, Applied Biosystems, Invitrogen) reduce adoption friction and support enterprise procurement.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Product recalls/quality issues could damage brand trust
- Share shifts to newer niche innovators in fast-moving categories
Leading indicators
- Customer satisfaction/NPS trends
- Warranty/field failure rates and major recall events
Counterarguments
- Instruments are often evaluated on performance/total cost rather than brand alone
Analytical Instruments
Analytical instruments (chromatography, mass spectrometry, electron microscopy) with consumables and services
Revenue_share uses Q1 2026 external-customer revenue of $1.667B divided by consolidated revenue of $11.005B. Operating_profit_share uses segment income of $355M normalized across $2.400B of rounded segment income. Source: Q1 2026 Form 10-Q.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Large installed base of instruments supports recurring revenue from consumables, software, and service contracts.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Third-party consumables and service providers reduce capture of aftermarket revenue
- Technology shifts can shorten instrument replacement cycles
Leading indicators
- Service and consumables revenue as a % of Analytical Instruments revenue
- Service contract renewal rates
Counterarguments
- Customers can standardize on open consumables and multi-vendor service where feasible
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Dense global sales/service presence and technical specialists improve uptime and reduce switching in mission-critical lab environments.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Remote/AI diagnostics and third-party service networks reduce differentiation
- Labor costs and retention challenges for field engineers
Leading indicators
- Field service response-time and uptime metrics (if disclosed)
- Service gross margin trend
Counterarguments
- Competitors also maintain strong global service teams; differentiation may be modest
Specialty Diagnostics
Specialty diagnostics (immunodiagnostics, microbiology, transplant diagnostics) and related consumables
Revenue_share uses Q1 2026 external-customer revenue of $1.124B divided by consolidated revenue of $11.005B. Operating_profit_share uses segment income of $313M normalized across $2.400B of rounded segment income. Source: Q1 2026 Form 10-Q.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Diagnostics menu and instrument placement drive recurring pull-through of reagents, culture media, and test kits.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Hospital and lab consolidation increases buyer bargaining power
- Rapid innovation cycles can displace assay menus
- Potential portfolio changes (divestitures) can alter scale advantages
Leading indicators
- Installed base and reagent pull-through growth (if disclosed)
- Regulatory warning letters or major quality events
Counterarguments
- Large IVD players can match menu breadth and compete aggressively on price
Laboratory Products and Biopharma Services
Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)
Revenue_share uses Q1 2026 external-customer revenue of $5.995B divided by consolidated revenue of $11.005B. Operating_profit_share uses segment income of $778M normalized across $2.400B of rounded segment income. Source: Q1 2026 Form 10-Q.
Distribution Control
Supply
Distribution Control
Strength
Durability
Confidence
Evidence
Large lab distribution platform with broad catalog and services creates one-stop procurement convenience and embeds Thermo Fisher in customer supply chains.
Distribution Control moat: definition, examples, and stocks
Erosion risks
- Disintermediation via manufacturer-direct and e-procurement marketplaces
- Large customers shifting to multi-vendor frameworks to force price competition
Leading indicators
- E-commerce penetration and digital procurement adoption
- Gross margin trend in Laboratory Products and Biopharma Services
Counterarguments
- Competitors with scale (e.g., Avantor/VWR) can offer similar catalog breadth and logistics
Procurement Inertia
Demand
Procurement Inertia
Strength
Durability
Confidence
Evidence
Product standardization and supply-chain-management services reduce procurement friction, increasing switching costs for enterprise customers.
Procurement Inertia moat: definition, examples, and stocks
Erosion risks
- Procurement organizations push periodic re-bids and standardize across vendors
- Digital marketplaces lower switching friction
Leading indicators
- Customer retention/renewal of supply agreements (if disclosed)
- Share of wallet with enterprise accounts
Counterarguments
- Switching distributors can be managed during contract re-bids; inertia may be limited
Evidence
...we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research...
Supports recurring consumables + instrument ecosystem in the segment.
...a suite of single-use solutions spanning the biologics workflow.
Single-use bioprocessing products are structurally consumable/recurring.
Our genetic sciences business combines a wide variety of instruments and related reagents...
Explicit linkage between instruments and reagents supports format/workflow lock-in.
...through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen...
Brand strength is positioned by the company as a differentiator in go-to-market.
...we provide a broad offering of instruments and the supporting consumables, software and services...
Directly describes the instrument + consumables/software/services model.
Showing 5 of 12 sources.
Risks & Indicators
Erosion risks
- Protocol standardization on open reagents reduces consumables differentiation
- Pricing pressure as competitors bundle similar bioprocessing consumables
- Funding cycles (NIH/academia) and biopharma demand volatility
- Open-source methods and third-party reagents reduce platform dependence
- New modalities can bypass incumbent instrument/reagent formats
- Product recalls/quality issues could damage brand trust
Leading indicators
- Consumables mix vs instruments mix
- Attach rate of proprietary reagents/kits to installed base
- Gross margin trend in Life Sciences Solutions
- Share of segment revenue from proprietary reagents/kits
- Installed base growth/decline for key platforms
- Customer satisfaction/NPS trends
Research TMO elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.